Surgical Sealants and Adhesives Global Market Report 2022: Biological Sealants, Synthetic Sealants, and Semi-Synthetic Sealants – Forecast to 2026 & 2031 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Surgical Sealants And Adhesives Global Market Report 2022” report has been added to ResearchAndMarkets.com’s offering. Major players in the surgical sealants and adhesives market are Baxter International Inc., B. Braun Melsungen AG, Cohera Medical, Inc., CryoLife Inc., C.R. Bard Inc., CSL Limited (CSL Behring), Johnson & Johnson (Ethicon, Inc.), Sanofi, Ocular Therapeutix Inc., … [Read more…]

MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022

New translational data suggests potential disease-modifying effects following treatment with pelabresib of both first-line and ruxolitinib-relapsed/refractory patients A comparative model suggests an improvement in SVR35 and TSS50 in JAK inhibitor-naïve myelofibrosis patients treated with pelabresib plus ruxolitinib over JAK inhibitors as monotherapy Additional presentations include positive interim data from the MANIFEST Phase 2 trial and … [Read more…]

MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress

– Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate – – 87.5% of Responses Achieved in First Two Cycles of Therapy, 75% of Complete Responses in first four cycles – – 9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event – – Primarily, Grade 3 AESIs to Date Occurred … [Read more…]

ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma

Overall response rate of 70.1% and complete response rate of 33.3% in heavily pretreated patients; median duration of response of 13.7 months Safety profile substantially consistent with prior findings Preparing for potential submission of a Biologics License Application to the FDA Cami data and diffuse large B-cell lymphoma posters to be presented today at the … [Read more…]

Genentech Announces Positive Data from Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting

– Long-term data at the European Hematology Association (EHA) 2022 Congress expands understanding of the impact of Genentech medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatment – – Updated data from Phase III CLL14 study of Venclexta (venetoclax) plus Gazyva (obinutuzumab) showed more … [Read more…]

New Report Highlights That the Czech Republic Could Serve as a Model for the EU in Addressing Smoking Prevalence

PRAGUE–(BUSINESS WIRE)–Ahead of the start of the Czech Presidency of the Council of the EU in July, the think tank Centre for Economic and Market Analysis (CETA) published the comparative study “A new approach towards tobacco legislation: the case for harm reduction in CEE and the EU” at an event in Prague. It presents a … [Read more…]

Consensus Cloud Solutions, Inc. Announces Pricing of Secondary Offering of 2,000,000 Shares Held by Ziff Davis

LOS ANGELES–(BUSINESS WIRE)–Consensus Cloud Solutions, Inc. (NASDAQ: CCSI) (the “Company” or “Consensus”) announced today the pricing of the previously announced underwritten offering of 2,000,000 shares of its common stock currently owned by Ziff Davis, Inc. (“Ziff Davis”), Consensus’s former parent company at a price of $41.00 per share (before underwriting discounts and commissions). Consensus is … [Read more…]

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

If approved, eli-cel will be the first and only gene therapy for the treatment of early active CALD, a rare neurodegenerative disease that primarily affects young children and leads to irreversible loss of neurologic function and death PDUFA goal date is set for September 16, 2022 SOMERVILLE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) today announced … [Read more…]

Arthritis National Research Foundation Announces 2022-23 Grant Recipients

Early-career scientists receive funding to pursue arthritis and related autoimmune disease research IRVINE, Calif.–(BUSINESS WIRE)–The Arthritis National Research Foundation (ANRF) today announced the 19 early-career scientists who will receive grant funding and make up the 2022-23 cohort. The eight first-year grantees will each receive $100,000 and for the first time, second year grantees will be … [Read more…]

Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent Dispute

TEL AVIV, Israel & PARSIPPANY, N.J.–(BUSINESS WIRE)–Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc., U.S. affiliates of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), have reached an agreement with Aurobindo to resolve the dispute over Aurobindo’s Abbreviated New Drug Application (“ANDA”) for a generic deutetrabenazine product. Teva and Aurobindo have been involved … [Read more…]